Skip to main content

Danahy Kevin Patrick's Form 4 filing

Pulse Biosciences, Inc. (PLSE) · filed Sep 22, 2025

Accession no.
0001437749-25-029646
Filed
Sep 22, 2025
Trade date
Sep 18-19, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $377.2K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Danahy Kevin PatrickCIK 0001913245Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 18, 2025Common StockMOption exerciseAcquired+20,000$1.53+$30,60063,298Direct
Sep 18, 2025Common StockSSaleDisposed−20,000$18.49F2−$369,80043,298Direct
Sep 19, 2025Common StockMOption exerciseAcquired+400$1.53+$61243,698Direct
Sep 19, 2025Common StockSSaleDisposed−400$18.48−$7,39243,298Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 18, 2025Common StockMOption exerciseDisposed−20,000$0.00$0430,000Direct
Sep 19, 2025Common StockMOption exerciseDisposed−400$0.00$0429,600Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $18.48 to $19.48 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)